09Jun 2014

Rheumatologists should be alert to osteomalacia in patients receiving tenofovir. The main complaint reported by these patients is diffuse pain, predominantly in the lower limbs, indicating multiple stress fractures. Serum phosphate and appropriate screening for abnormal proximal tubule function should be monitored. Bone scintigraphy should be carried out in cases of limb pain before the occurrence of more severe complications.

20May 2014

The management of women with osteoporotic vertebral

fractures includes measures to reduce pain providing early mobility, to support the affected spine ensuring fracture healing, as well as starting treatment for osteoporosis itself. Any other underlying pathology should be sought and treated. Early detection and treatment is essential as there is an increased risk of further fractures in patients with vertebral fractures. Treatment will depend on the underlying causes of bone loss, efficacy in any particular situation, cost and patient preference.

08Abr 2014

Patients with chronic hepatitis C have low bone mass associated with increased bone resorption, and some relationship can be expected between serum aminotransferase levels and the degree of bone mass loss.

Bone mass may be improved and bone turnover normalized in patients who respond to antiviral therapy. Elevated serum sTRFR-55 levels may play a role in the bone mass loss of these patients.

Autor: Redondo-Cerezo E, Casado-Caballero F, Martin-Rodriguez JL, Hernandez-Quero J, …

08Abr 2014

Roux-en-Y gastric bypass increased circulating osteopontin levels, while they remained unaltered after sleeve gastrectomy.

The increase in osteopontin levels after Roux-en-Y gastric bypass could be related to the increased bone resorption in relation to its well-known effects on bone of this malabsorptive procedure in comparison to the merely restrictive sleeve gastrectomy.

Autor: Lancha A1, Moncada R, Valentí V, Rodríguez A, Catalán V, Becerril S, Ramírez B, Méndez-Giménez L,.

08Abr 2014

Denosumab increased significantly bone mass in all three dual X-ray absorptiometry standard sites, while alendronate did not at total hip.

No benefit was observed in men previously treated with alendronate who switched to denosumab treatment.

Autor: Planas Morin J, Celma Domenech A, Placer Santos J, Trilla Herrera E, Salvador Lacambra C,…